Delivery Order SPE2DR25D2013-SPE2DR26F5QLF
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,044.82 to supply Micardis HCT 80-25 mg tablet unit dose packages (30 count) with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price contract is non-set-aside and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical supply...
- The Defense Logistics Agency awarded a $2,599.68 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Micardis HCT 40-12.5 mg tablet unit dose packs (30 count). This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,772.81 to AmerisourceBergen Drug Corp for Micardis HCT 40-12.5 mg tablets (30-count unit dose packaging) with a completion deadline of September 11, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,359.97 to AmerisourceBergen Drug Corp for the supply of Micardis HCT 80-25 mg tablets in unit dose packaging (30 count). This is a firm fixed-price delivery order with an ultimate completion date of September 29, 2025, and represents a non-set-aside competitive award. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a delivery order valued at $5,163.02 to AmerisourceBergen Drug Corp for the supply of MICARDIS HCT 40-12.5 mg tablets in unit dose packaging (30 count) on September 2, 2025, with completion expected by September 3, 2025. This contract was awarded on a non-competitive, firm fixed-price basis and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at approximately $1 billion through...
- The Defense Logistics Agency awarded a delivery order valued at $3,631.02 to AmerisourceBergen Drug Corp for the supply of Micardis HCT 40-12.5 mg tablets in unit dose packaging (30 count) on August 11, 2025, with completion due by August 12, 2025. This is a firm fixed price delivery order with no set-aside designation, performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen Drug Corp's larger prime indefinite delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,118.82 to AmerisourceBergen Drug Corp for Micardis HCT 80-25 mg tablets (unit dose, 30-count packaging) with a firm fixed price structure. This contract, issued on August 5, 2025, with completion targeted for August 6, 2025, represents a competitively awarded procurement with no set-aside designation. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,416.12 to AmerisourceBergen Drug Corp for MICARDIS HCT 40-12.5 mg tablets (30-count unit dose packages) on September 15, 2025, with completion scheduled for September 16, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a $1,243.66 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 4, 2025, for the supply of Micardis HCT 40-12.5 mg tablets (30 unit dose tablets). This competitively awarded, non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be performed and delivered from the contractor's facility in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Micardis HCT 40-12.5 mg tablets (unit dose, 30 count) with a contract value of $3,124.61. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order...
- SPE2DR25D2013Indefinite Delivery Contract
- SPE2DR25D2013-SPE2DR26F5QLFDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,271.12 to AmerisourceBergen Drug Corp for the supply of Micardis HCT 80-25 mg tablets (30-count unit dose packaging) with a completion date of November 5, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be delivered to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal military and veteran healthcare procurement. The company's comprehensive IDC vehicle enables the supply of brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains to support Defense Health Agency and other government healthcare systems globally. This specific delivery order for an antihypertensive combination medication reflects the company's ongoing role in fulfilling pharmaceutical supply requirements through the DLA's medical supply chain network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 11/4/25 |